GLOBAL ASSETS · ALPHA RESEARCH · ISSUE 001

Do Not Chase AI Growth—Medical Value Is Beginning to Re-rate

Weekly Alpha Research | Issue 001 | 4 September 2026

Samsara has the stronger fundamental confirmation, but its post-earnings gap weakens the entry. Medtronic’s improving fundamentals are moving ahead of valuation re-rating, offering the cleaner small-trial setup.

Growth Alpha · IOTValue Alpha · MDTSelective Trial

WEEKLY VERDICT

One waits for price. One earns a trial.

IOT is the stronger Growth / Structural Alpha candidate, but the correct action is to wait. MDT is the more comfortable Value / Rotation setup and can enter a 0.5%–1% trial in the defined zone.

IOT · SAMSARA3/4WAIT｜DO NOT CHASE

MDT · MEDTRONIC3/4SMALL TRIAL

01 · ALPHA DECISION BOARD

This week’s decision board

Asset	Type	Score	Status	Action	Position
IOT · Samsara	Growth / Structural	3/4	Trial Candidate	Wait for gap digestion	0.5%–1%
MDT · Medtronic	Value / Rotation	3/4	Trial Candidate	$90–94 Trial Zone	0.5%–1%
03696 · Insilico	AI Biotech Alpha	3/4	Keep Trial	Wait for BD / clinical proof	0.5%–1%
ARES	Private Credit	3/4	Watch	Credit gate remains yellow	0%
CRCL · Circle	Digital Finance	3/4	Watch / No Add	Wait for Arc	No upgrade
FIG · Figma	AI Software	2/4	Watch	Wait for earnings / valuation	0%
RKLB	Space	2/4	Watch	Neutron remains the gate	No upgrade
06030 · CITIC Securities	Rotation	2/4	4–8W Watch	Wait for breakout	0%

02 · GROWTH / STRUCTURAL ALPHA

Samsara｜NYSE: IOT

Physical AI is becoming an operating platform—but the stock has run ahead of the entry

Why now: The market often reduces Physical AI to robots and autonomy. Samsara digitizes fleets, equipment, plants, warehouses, drivers and field operations, then applies AI to safety, maintenance, routing and efficiency. It is already a multi-billion-dollar ARR platform, not a concept trade.
What changed: Large enterprises are expanding Samsara from a fleet tool into a Physical Operations Platform. Multi-product penetration and cross-sell are rising, showing customers entrusting more real-world workflows to one system.
Evidence and valuation: FY27 Q2 ARR, net-new ARR, large-customer count and large-customer ARR remained strong; revenue grew about 30% and guidance rose. Yet the post-print jump leaves only a half-green valuation signal. Fundamental confirmation does not automatically confirm the entry.
Action: Do not chase. Path one: consider a 0.5% trial only if $40–42 is retested and holds. Path two: if no pullback comes, require 3–5 trading days of consolidation before reassessment. Target: 0.5%–1%; discuss 2%–3% only after another quarter of proof.
What changes our mind: Downgrade if ARR growth falls clearly below the mid-to-high 20% range, million-dollar customer growth slows materially, new products fail to lift ACV, or margins deteriorate.

Next review: 18 Sep 2026 · Catalyst window: Sep–Dec 2026

03 · VALUE / ROTATION ALPHA

Medtronic｜NYSE: MDT

Fundamentals are changing before the market changes the label

Why now: Medtronic is still widely viewed as a stable but slow medtech incumbent. Q1 FY27 challenged that label: broad-based growth, stronger cardiovascular performance and raised revenue and EPS guidance show a measurable change in slope.
Fundamental evidence: Revenue reached $9.756 billion and organic growth was 13.7%, helped by an extra fiscal week. Cardiovascular grew 18.9% organically and Cardiac Ablation Solutions grew 88%. FY27 organic growth guidance rose to 7.25%–7.75% and non-GAAP EPS guidance to $5.94–$6.00.
Why the asymmetry is better: The post-print reaction was moderate, leaving fundamental evidence ahead of price re-rating. Valuation remains near a mature medtech range with roughly a 3% dividend yield. Repeated 7%+ organic growth could force the market to reclassify the company.
Action: MDT is suitable for a 0.5%–1% trial at $90–94. A hold above $96–98 plus another quarter of operating confirmation can upgrade it toward Confirmed. Initial target: 0.5%–1%; confirmed target: 2%–3%.
What changes our mind: Downgrade if next-quarter organic growth falls below the raised annual range, cardiovascular momentum cools sharply, or FY27 revenue / EPS guidance is cut.

Next review: 2 Oct 2026 · Catalyst window: Sep–Nov 2026

04 · ACTIVE WATCH LIST

Material changes—not ticker collection

Keep Trial｜Positive Bias

03696 · Insilico Medicine

A large zero-coupon convertible extends runway, first-half revenue and profit improved, and management signaled personal buying. Financing and commercialization evidence strengthened, but a major BD/licensing deal, positive cash flow or a clinical readout is still required for an upgrade.

Watch｜Risk Gate Yellow

ARES

Fundraising, AUM and platform expansion remain strong, but private credit requires an additional check on defaults, redemptions and non-accruals. Strong flows cannot override the credit-risk floor.

Watch / No Add

CRCL · Circle

USDC and onchain volume continue to support the long-term thesis, with Arc as the next key node. A consortium stablecoin from large financial institutions raises competitive risk, so no add for now.

Watch

FIG / RKLB / KKR / CITIC Securities

FIG awaits earnings and valuation digestion. Electron execution remains solid, but Neutron is still RKLB’s upgrade gate. KKR shows no material change. CITIC Securities enters a 4–8 week rotation watch pending breakout and relative strength.

05 · 90-DAY RULE

Research does not earn permanent residency

IOT and MDT begin their 90-day clock on 4 September. If neither gains new confirming evidence by roughly 3 December, each must re-prove its place on the active list. Every Watch or Trial requires a next review date and catalyst window.

06 · POSITION DISCIPLINE

Positions must be earned

Trial · 0.5%–1%
Confirmed Alpha · 2%–3%
High Conviction · 3%–5%
Single Alpha ≤5%
Total Alpha sleeve ≤15%

07 · KEY TERMS

Key Terms

Gap: A price jump that opens materially above the prior trading range after an event.
Trial: A small test position after initial evidence, before full confirmation.
Organic Growth: Revenue growth excluding currency, acquisitions, divestitures and other discrete effects.
PFA: Pulsed-field ablation, using electrical pulses to treat cardiac arrhythmias.
Risk Gate: A hard fundamental and risk threshold that even a high-scoring opportunity must pass.

08 · PRIMARY SOURCES

Sources and research boundary

Company-reported figures are used to validate the Master Research. Price zones and position sizes are research framework outputs, not individualized investment advice.

Samsara Investor Relations Medtronic Q1 FY2027 Results Circle Q2 2026 Results